2025. Patients With Cardiovascular Risk Factors and Atopic Dermatitis: Long-Term Safety of Upadacitinib for Major Adverse Cardiovascular Events, Venous Thromboembolism, or Malignancy (Excluding Nonmelanoma Skin Cancer). SKIN The Journal of Cutaneous Medicine. 9, 6 (Nov. 2025), s612. DOI:https://doi.org/10.25251/m9gw3y80.